Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | METAP2 | P50579 | 3/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | WDR5 | P61964 | 1/20 | 0.54 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498858 | 0.86 | MMP2 (0.60) | MEN1KMT2AMMP2ATMGAA | |
| SCHEMBL5072751 | 0.84 | MEN1 (0.71) | MEN1KMT2AMETAP2MMP2ATM | |
| SCHEMBL3982318 | 0.84 | METAP2 (0.60) | MEN1KMT2AMETAP2MMP2ATM | |
| SCHEMBL14301206 | 0.84 | MEN1 (0.67) | MEN1KMT2AMMP2ATMGAA | |
| SCHEMBL3985574 | 0.81 | METAP2 (0.60) | MEN1KMT2AMETAP2SLC16A3KCNA5 | |
| SCHEMBL5072749 | 0.80 | MMP2 (0.60) | MEN1KMT2AMMP2ATMGAA | |
| SCHEMBL7820192 | 0.79 | MEN1 (1.00) | MEN1KMT2AMETAP2ATMGAA | |
| SCHEMBL22000089 | 0.79 | ACLY (0.72) | MEN1KMT2AMMP2GAASLC16A3 | |
| SCHEMBL15689784 | 0.77 | PKLR (0.65) | MEN1KMT2AMMP2ATMGAA | |
| SCHEMBL15689758 | 0.77 | PKLR (0.62) | MEN1KMT2AMMP2ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7119120-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | MEN1 2905/4885KMT2A 4536/4885METAP2 1689/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | MEN1 2248/4885KMT2A 4634/4885METAP2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.